By Lina carolina 
An MRI-based imaging technique developed at the University of Cambridge predicts the response of ovarian cancer tumours to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models. This groundbreaking advancement, detailed in the journal Oncogene, holds the potential to revolutionize how ovarian cancer is managed, offering oncologists unprecedented speed in tailoring therapies and improving patient outcomes.
Revolutionizing Ovarian Cancer Treatment: A New Era of Precision
Ovarian cancer, particularly the high-grade serous subtype (HGSOC), remains one of the most challenging and lethal gynecological malignancies. Diagnosed annually in approximately 7,500 women in the UK, with around 5,000 cases involving the aggressive HGSOC form, the disease’s insidious nature often leads to late diagnosis and widespread metastasis. Current survival rates underscore the urgency for more effective diagnostic and therapeutic strategies; in England, only 43% of women survive five years beyond diagnosis. A significant hurdle in treatment has been the prolonged waiting period for patients and clinicians to ascertain treatment efficacy, often stretching into weeks or months. This delay can mean that patients continue to receive ineffective therapies, allowing the cancer to progress and potentially become resistant to further interventions.
The newly developed technique, known as hyperpolarized carbon-13 imaging, offers a paradigm shift by dramatically amplifying the signal detected by MRI scanners – by more than 10,000 times. This amplification allows scientists to visualize metabolic processes within tumors at an unprecedented level of detail. Crucially, the Cambridge researchers have demonstrated that this technique can differentiate between distinct subtypes of ovarian cancer, thereby predicting their sensitivity to specific treatments.
Unveiling Tumor Subtypes and Treatment Sensitivity
The researchers employed patient-derived cell models that meticulously replicate the complex behavior of human high-grade serous ovarian cancer. Through hyperpolarized carbon-13 imaging, they were able to clearly distinguish whether a tumor was sensitive or resistant to Carboplatin, a cornerstone of first-line chemotherapy for ovarian cancer. This capability is monumental because different forms of ovarian cancer exhibit varying responses to drug treatments.
"This technique tells us how aggressive an ovarian cancer tumour is, and could allow doctors to assess multiple tumours in a patient to give a more holistic assessment of disease prognosis so the most appropriate treatment can be selected," stated Professor Kevin Brindle, senior author of the report and a leading figure at the University of Cambridge’s Department of Biochemistry. Professor Brindle, who also holds an affiliation with the Cancer Research UK Cambridge Institute, has dedicated two decades to advancing hyperpolarized carbon-13 imaging for a range of cancers, including breast, prostate, and glioblastoma, where similar metabolic variations predict treatment response.
A Timeline of Innovation and Early Successes
The journey towards this breakthrough has been a long-term commitment. Professor Brindle’s work on hyperpolarized carbon-13 imaging dates back twenty years, with initial clinical applications showing promise. A significant milestone was reached in 2020 with the first clinical study in Cambridge focusing on breast cancer patients, which further validated the technique’s potential. This latest research, published today in Oncogene, represents a critical step forward specifically for ovarian cancer, building upon years of foundational research and validation across multiple cancer types. The current study’s focus on patient-derived cell models marks a crucial transition from laboratory bench to potential clinical application, offering a robust platform for demonstrating the technique’s predictive power before moving to human trials.
Comparative Analysis: Hyperpolarized Imaging vs. PET Scans
In a significant aspect of their research, the Cambridge team compared the performance of hyperpolarized carbon-13 imaging against Positron Emission Tomography (PET) scans, a widely utilized tool in current clinical practice. The findings revealed a stark contrast: PET scans were unable to detect the subtle metabolic differences that characterize distinct ovarian tumor subtypes, and consequently, could not reliably predict the tumor type present. This highlights a critical limitation of current imaging modalities in providing the granular information needed for personalized treatment selection. Hyperpolarized carbon-13 imaging, on the other hand, demonstrated its superior ability to discern these vital metabolic signatures.
The Promise of Rapid Feedback and Personalized Medicine
The implications of this rapid feedback mechanism are profound. Oncologists will be empowered to predict a patient’s likely response to treatment and, critically, to monitor treatment efficacy within a mere 48 hours. This accelerated insight will enable swift adjustments to treatment plans, moving away from the current paradigm of lengthy waiting periods. For patients with ovarian cancer, especially those with advanced disease, this means the possibility of quickly transitioning to the most effective therapy, minimizing exposure to ineffective treatments and their associated side effects, and potentially halting disease progression sooner.
Professor Brindle emphasized the patient-centric benefits: "One of the questions cancer patients ask most often is whether their treatment is working. If oncologists can speed their patients onto the best treatment, then it’s clearly of benefit."
Addressing the Challenge of Multi-Tumor Disease
Ovarian cancer often presents as multiple tumors spread throughout the abdominal cavity. Obtaining biopsies from all these disseminated tumors is often impossible, and even if feasible, the tumors may harbor different subtypes with divergent treatment sensitivities. The non-invasive nature of MRI, coupled with the enhanced sensitivity of hyperpolarized carbon-13 imaging, offers a unique advantage. It allows oncologists to assess all tumors simultaneously, providing a more comprehensive and holistic view of the disease burden and its characteristics.
"We can image a tumour pre-treatment to predict how likely it is to respond, and then we can image again immediately after treatment to confirm whether it has indeed responded," Professor Brindle elaborated. "This will help doctors to select the most appropriate treatment for each patient and adjust this as necessary."
How the Technique Works: A Glimpse into Cellular Metabolism
At its core, hyperpolarized carbon-13 imaging utilizes an injectable solution containing a specially ‘labeled’ form of pyruvate, a naturally occurring molecule in the body. Once administered, this labeled pyruvate enters the body’s cells. The MRI scanner then visualizes the rate at which this pyruvate is metabolized into lactate. This metabolic conversion rate acts as a direct indicator of the tumor’s subtype and, consequently, its inherent sensitivity or resistance to specific treatments. This metabolic fingerprint provides a dynamic window into the tumor’s internal workings, far beyond what conventional imaging can reveal.
Future Directions: Towards Clinical Implementation
The immediate next step for the Cambridge team is to translate these promising findings from patient-derived cell models into clinical trials with actual ovarian cancer patients. The scientists anticipate initiating these trials within the next few years, a crucial phase that will determine the technique’s real-world applicability and refine its diagnostic protocols for widespread clinical use.
The broader implications of this research extend beyond ovarian cancer. The underlying principle of hyperpolarized carbon-13 imaging – its ability to reveal metabolic differences and predict treatment response – has already shown utility in other aggressive cancers. Its application in breast cancer, prostate cancer, and glioblastoma underscores its versatility and potential to impact a wide spectrum of oncological care. The ongoing validation across different cancer types strengthens the case for its integration into routine clinical practice, promising a future where cancer treatment is more precise, more rapid, and ultimately, more effective. The development of this imaging technique represents a significant stride in the ongoing battle against cancer, offering hope for improved prognoses and a better quality of life for patients.
